On April 20, Shanghai Kehua Bio-Engineering Co.Ltd(002022) disclosed the performance express. In 2021, the company is expected to achieve a total operating revenue of 4.469 billion yuan, a total profit of 1.384 billion yuan and a net profit attributable to shareholders of listed companies of 721 million yuan, an increase of 7.55%, 2.07% and 6.76% respectively over the same period of the previous year. (Note: due to the refusal of the management of Tianlong company, the above data does not include the financial data of Tianlong company in the fourth quarter.)
At the same time, Shanghai Kehua Bio-Engineering Co.Ltd(002022) issued a risk warning announcement. As the management of the holding subsidiary Tianlong company violated the regulations of the listed company on the management rules and regulations of the holding subsidiary and the articles of association of Tianlong company, refused to implement the resolutions made by the board of directors of Tianlong company, refused to cooperate with Lixin accountant to carry out the audit work in 2021, and refused to provide important information such as the financial books of Tianlong company in 2021, This may lead to the company’s 2021 annual financial report being issued with “unable to express an opinion” audit report by Lixin accountant. According to the Listing Rules of Shenzhen Stock Exchange, the company’s shares may be subject to delisting risk warning. Please pay attention to the investment risk.
According to public information, Shanghai Kehua Bio-Engineering Co.Ltd(002022) disclosed the announcement of major events on December 28, 2021, and Li Ming, general manager of Tianlong company, the holding subsidiary of the company, sent a letter to the chairman, President and chief financial officer of the company via email on December 25, 2021, saying that he was unable to cooperate with the preliminary review of accounting statements and subsequent audit of listed companies at present.
Shanghai Kehua Bio-Engineering Co.Ltd(002022) believes that the company legally holds 62% of the equity of Tianlong company and is the controlling shareholder of Tianlong company. Tianlong company accepts the audit of the audit institution entrusted by the company, which is not only its responsibility as a holding subsidiary of the listed company, but also its obligation stipulated in the articles of association. The management and relevant responsible persons of Tianlong company shall not obstruct the normal audit work of listed companies on the basis of disputes between shareholders of Tianlong company.
It is understood that Shanghai Kehua Bio-Engineering Co.Ltd(002022) has always been patient and hopes that the two sides can properly resolve the audit differences and ensure that the audit of Tianlong’s 2021 annual report and the audit and information disclosure of the company’s 2021 annual report can be completed on time. Since the release of the announcement of major events, the company and Lixin accountants have actively communicated with Tianlong company for many times to urge it to fulfill its obligations and cooperate with the audit, but the other party has not cooperated.
Shanghai Kehua Bio-Engineering Co.Ltd(002022) said that due to Tianlong’s violation of regulations and refusal to cooperate in the audit work, the company’s 2021 financial report may be issued with an “unable to express an opinion” audit report. As the controlling shareholder of Tianlong company, Shanghai Kehua Bio-Engineering Co.Ltd(002022) will continue to actively exercise the management rights of the listed company over its holding subsidiaries, and take all legal and necessary measures to resolutely safeguard the legitimate rights and interests of the company and shareholders, especially small and medium-sized shareholders.
